Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
life sciences
national blog main
7
×
boston blog main
boston top stories
clinical trials
boston
fda
biotech
drugs
alnylam pharmaceuticals
aminolevulinic acid
deals
detroit blog main
detroit top stories
eli lilly
givosiran
indiana blog main
indiana top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
rna interference
roche
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alprazolam
amgen
bempedoic acid
biontech
biopharma
blueprint medicines
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
What
second
7
×
drug
fda
medicine
new
rna
approval
alnylam
approved
cancer
deal
interference
medicines
nod
oks
pharmaceutical
pharmaceuticals
rnai
seek
speedy
therapeutics
time
won
acute
addresses
ago
bets
betting
billion
bio
biopharma
causes
cholesterol
cleared
combo
comes
companies
condition
cut
data
Language
unset
Current search:
second
×
photo
×
" national blog main "
×
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines